Peide Biopharma Secures Tens of Millions in Pre-A Funding to Advance Peptide Drug Pipeline

　　【Pharmaceutical Network Enterprise NewsRecently, PDBio announced the completion of a multi-million yuan Pre-A round of financing. This round was led by the Sichuan Development Academician Fund, with participation from Huaxi Securities and other institutions. The funds will mainly be used for the research and development of new peptide drug pipelines.
 

Data shows that PDBio has built a hundred-million-level natural peptide library from venomous animals. Based on the targeted mining system for animal venom peptides, the company screens and develops peptide drugs through a "high-throughput + cloud computing" screening platform and AI technology.
 

According to reports, peptide drugs are expected to break the current dilemma of high difficulty in small molecule drug research and development and increasing homogeneity among emerging large molecule drugs such as antibodies. With breakthrough progress in diabetes and weight loss indications represented by GLP-1RA peptide drugs such as semaglutide and tirzepatide, as well as active exploration in new fields like cardiovascular diseases, chronic kidney disease, heart failure, non-alcoholic fatty liver, and Alzheimer's disease, the future market prospects for peptide drugs are broad. Moreover, under the high technical barriers, the demand for peptide CDMO will also grow increasingly strong. The promising market outlook is attracting pharmaceutical companies to enter the field and capital to continuously increase its investment.
 

Apart from PDBio, multiple peptide drug manufacturers have received financing support since 2023. For instance, on December 1, 2023, Perpetual Medicines announced that it had completed an $8 million seed round led by Becoming Capital to advance its highly integrated computational design-automated synthesis peptide drug discovery platform. The company aims to build the next-generation peptide drug discovery engine, attempting to accelerate the discovery process and improve the quality of peptide drug candidates in previously undruggable targets and disease areas. Through this funding, the company will advance its lead programs into clinical stages and continue to build its preclinical portfolio in the fields of oncology, autoimmune diseases, and metabolic disorders.
 

In September 2023, Chengdu Tachem Co., Ltd. completed a 200 million yuan Series A financing round in August 2023. The funds from this round will be used to accelerate the production of the company's 270-mu Phase I factory, with plans to add 500 tons of Fmoc amino acid capacity by 2024. The funds will also be used for the construction of a 230-mu Phase II factory in 2024 to further meet the growing global demand for Fmoc amino acids. The company specializes in protected amino acids and peptide drugs.Intermediate, committed to continuously building a modern peptide supply chain system that is independently controllable, secure, reliable, and highly competitive.
 

On August 7, 2023, XIUSHI announced the completion of an angel round of financing worth tens of millions of yuan, with this round being invested by Shicui Capital. The funds will mainly be used to enhance the company's innovative polypeptide biosynthesis technology platform and new product development, expand the production capacity of existing products, and promote the application and promotion of advantageous technologies and products both domestically and internationally. It is reported that the company is a provider of polypeptide drug biosynthesis solutions, primarily offering solutions for the biosynthesis of polypeptide drugs.
 

　　......
 

According to Frost & Sullivan data, the global and Chinese peptide drug market size will achieve a CAGR of 8.9% and 16.4%, respectively, from 2020 to 2025. The global peptide drug market size is expected to grow from USD 62.8 billion in 2020 to USD 96 billion in 2025, while the Chinese peptide drug market size will increase from USD 8.5 billion in 2020 to USD 18.2 billion in 2025. Additionally, according to Frost & Sullivan, the global peptide CDMO market size is expected to grow from USD 2.2 billion in 2021 to USD 11.8 billion by 2030, with a CAGR of 21%; the Chinese peptide CDMO market size is expected to grow from RMB 1.3 billion to RMB 18.5 billion, with a CAGR of 34%.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.